Green Core
VC Fund
Tokyo, Japan
Green Core is an investment firm.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Green Core invests in
Stages Green Core invests in
Countries Green Core invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $2M–$4.8M
Investment Focus
Industry
- Pharmaceutical 4 (50%)
- Health Care 3 (38%)
- Medical 2 (25%)
- Biotechnology 2 (25%)
- Medical Device 2 (25%)
Stage
- Series A 4 (50%)
- Seed 3 (38%)
- Funding Round 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ryusuke Honjo
CEO
|
CEO | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
JiMED designs & develops AI based brain-computer interface for implant in ALS patients to improve communication. | $2M / Jun 18, 2026 | |
|
|
Cosomil develops early diagnostic drugs for diseases and provides research and development support to healthcare companies. | Series A / Feb 06, 2026 | |
|
|
Physiologas Technologies is a manufacturing company that designs and develops medical equipment for the healthcare industry. | $2M / Series A / Aug 19, 2025 | |
|
|
JiMED designs & develops AI based brain-computer interface for implant in ALS patients to improve communication. | $2.3M / Series A / Feb 13, 2025 | |
|
|
Horizon Illumination Lab Optics conducts programs to enhance research related to fluorescent bioimaging technology. | Seed / Nov 29, 2024 | |
|
|
A-SEEDS, an innovative biotech company sprouted from Shinshu University, is dedicated to pioneering advanced treatments for life-threatening cancers. Harnessing the potential of non-viral genetic engineering, our cutting-edge immune cell therapy opens up new horizons of hope for patients seeking effective and transformative solutions. | $3M / Seed / Jan 04, 2024 | |
|
|
Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment. | $4.8M / Series A / Dec 22, 2023 | |
|
|
Cosomil develops early diagnostic drugs for diseases and provides research and development support to healthcare companies. | Seed / Nov 29, 2023 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Green Core invest in?
Green Core invests primarily in Pharmaceutical, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Green Core's check size?
Green Core typically joins rounds of $2M–$4.8M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Green Core participates in.
How do I contact Green Core?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Green Core?
The team at Green Core includes Ryusuke Honjo (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!